AtriCure, Inc. $ATRC Shares Newly Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 79,365 shares of the medical device company’s stock, valued at approximately $4,460,000. Lisanti Capital Growth LLC owned approximately 0.16% of AtriCure at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fulcrum Asset Management LLP acquired a new stake in shares of AtriCure in the third quarter valued at approximately $92,000. Brighton Jones LLC acquired a new stake in shares of AtriCure during the third quarter valued at about $279,000. Ethic Inc. acquired a new position in AtriCure during the third quarter worth $203,000. Provenance Wealth Advisors LLC acquired a new stake in shares of AtriCure during the third quarter worth about $217,000. Finally, Oregon Public Employees Retirement Fund purchased a new position in AtriCure in the 3rd quarter valued at approximately $641,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ATRC shares. Piper Sandler restated an “overweight” rating and set a $70.00 target price (up from $60.00) on shares of AtriCure in a research note on Wednesday, November 4th. UBS Group cut shares of AtriCure from a “buy” rating to a “sell” rating in a report on Wednesday, October 21st. Needham & Company LLC increased their price target on shares of AtriCure from $64.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Stifel Nicolaus set a $65.00 price target on AtriCure in a research note on Thursday, September 17th. Finally, Canaccord Genuity Group upped their price objective on AtriCure from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $61.80.

Insider Activity at AtriCure

In other AtriCure news, insider Salvatore Privitera sold 8,404 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total value of $546,260.00. Following the completion of the transaction, the insider directly owned 134,341 shares of the company’s stock, valued at $8,732,165. This represents a 5.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl S. Dahlquist sold 9,370 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 39,026 shares of company stock valued at $2,172,263. Corporate insiders own 4.00% of the company’s stock.

AtriCure Trading Up 2.3%

Shares of ATRC stock opened at $57.53 on Thursday. The firm’s 50 day moving average price is $57.32 and its two-hundred day moving average price is $39.00. The company has a quick ratio of 3.29, a current ratio of 4.33 and a debt-to-equity ratio of 0.17. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $66.02. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of 191.77 and a beta of 1.23.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.23. The company had revenue of $154.45 million for the quarter, compared to analysts’ expectations of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. On average, analysts anticipate that AtriCure, Inc. will post 0.44 EPS for the current year.

AtriCure Company Profile

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.